Cessatech Denmark

Cessatech and Proveca announce world-wide excluding US commercial partnership for CT001

Cessatech and Proveca enter an exclusive agreement for the commercialization of CT001 world-wide excluding US.Proveca has been granted a non-exclusive option to license Cessatech's CT002 program.Proveca is a global pharmaceutical company specialising in the development and licensing of medicines to address the unmet medical needs in children. Proveca is based in Manchester, England.View original content:https://www.prnewswire.co.uk/news-releases/cessatech-and-proveca-announce-world-wide-excluding-us-commercial-partnership-for-ct001-302230247.html